Melanoma is the most malignant and aggressive form of skin carcinoma originating in the pigment-producing melanocytes. In this study, to further investigate the molecular mechanisms of the development and progression of melanoma, we explored the impacts of long non-coding RNA (lncRNA) CASC2 on melanoma cell functions. Microarray analysis was carried out to identify the expression of lncRNA CASC2 in melanoma cells. MiR-181a was predicted as a sponging target of CASC2 by miRcode, while the 3′-UTR of Plexin C1 (PLXNC1) was a potential target of miR-181a according to the TargetScan database. The correlation among CASC2, miR-181a, and PLXNC1 was verified by dual luciferase reporter assay and qRT-PCR. After manipulation of CASC2, miR181a and PLXNC1 expression with transfection in A375 and M14 cells, cell viability, apoptosis, and invasive ability were evaluated using CCK-8, flow cytometry and Transwell assays, respectively. A low expression of CASC2 was detected in melanoma tissues and cells. Dual luciferase reporting assay confirmed that miR-181a targeted the 3′-UTR of PLXNC1. Furthermore, CASC2 could efficiently sponge miR-181a, thereby facilitating the expression of PLXNC1. Up-regulation of CASC2 suppressed the cell proliferation and invasion, but induced the apoptosis of melanoma cells. Our results demonstrated that lncRNA CASC2 can promote PLXNC1 expression by sponging miR181a, thereby inhibiting the proliferation and invasion of melanoma cells, indicating that lncRNA CASC2 functions via the miR-181a/PLXNC1 axis in melanoma.
Introduction
Melanoma is the most malignant and aggressive form of skin carcinoma originating in pigment-producing melanocytes. Melanoma is primarily caused by ultraviolet radiation from sunshine or tanning devices. It is usually curable before tumor metastasis, but if not diagnosed and treated early, it can be an intractable and fatal disease. The incidence of melanoma is steadily increasing. In 2016, it was estimated that there were 76,380 new cases in the United States, with 46,870 occurring in males and 29,510 in females. According to the latest cancer statistics in 2017, the number of cases of melanoma is projected to increase to 87,110, with 52,170 in males and 34,940 in females [1, 2] . Besides primary surgery, treatment strategy for stage III/IV melanoma has been introduced in recent years, including adjuvant immunotherapy and gene-targeted therapy in spite of their side effects [3] . Exploring potential therapeutic strategies against melanoma remains a research focus.
Advances in human RNA sequencing technologies have revealed that non-coding RNAs make up the majority (more than 90%) of the whole genome, while only 2% are protein-coding genes [4] . Non-coding RNAs can be divided into two categories according to their size. Long non-coding RNAs (lncRNAs) are considered as important regulators of gene expression and are involved in a wide range of pre-and post-transcriptional functions, such as nuclear architecture and import, immunity, imprinting, cellular trafficking, splicing, and precursors of smaller RNAs [5] . Studies have revealed the aberrant expression of many lncRNAs in various cancers and their effects on tumorigenesis, maintenance, and development. For instance, Liu et al. [4] found that lncRNA SNHG15 contributes to osteosarcoma cell proliferation, invasion, and autophagy, while Ou et al. [6] identified that lncRNA H19 acts as a molecular sponge of miR-138-5p in cervical cancer. These findings make lncRNAs potential therapeutic targets for tumor treatments. LncRNA cancer susceptibility candidate 2 (CASC2) is located on chromosome 10 in humans [7] and has been reported as a tumor suppressor in human malignancies such as glioma [8] , non-small cell lung cancer [9] , colorectal cancer [7] , renal cell carcinoma [10] , gastric cancer [11] , hepatocellular carcinoma [12] , and thyroid carcinoma [13] . Although there is evidence for the clinical significance of CASC2 in various tumors, its molecular mechanism in melanoma cells remains unknown.
The second category of non-coding RNAs is known as small ncRNAs. MicroRNAs, as a family of small ncRNAs, are approximately 22 nucleotides in length. They act as post-transcriptional regulators by pairing to the 3′-untranslated regions (3′-UTRs) of their target mRNAs [14] . Recent studies have shown the association between various mRNAs and melanoma progression. For example, miR-137, miR-605, and miR-493 could function as tumor suppressors by targeting different genes [15] [16] [17] , while miR-301a could be an oncogene in malignant melanoma [18] and miR-769 might promote cell proliferation during the development of human melanoma [19] . MiR-181a has been generally reported as a tumor promoter in previous studies. Dysregulation of miR-181a has been discovered in various cancers including hepatocellular carcinoma (HCC) [20] , osteosarcoma [21] , cervical cancer [22] , and other cancers. However, few studies have focused on the biological functions of miR-181a in human melanoma, which deserves to be explored.
Plexin C1 (PLXNC1) is a subfamily of plexin gene family located on chromosome 12 [23] . Plexin C serves as a receptor for Semaphorin 7a [24] . Balakrishnan et al. [23] analyzed the plexin gene family in human tumors and found that multiple mutated plexin genes including PLXNA4, PLXNB3, and PLXNC1 may be involved in cancer progression. Kumasaka et al. [24] reported that PLXNC1 may be associated with an endothelin receptor B-mediated signaling for tumor suppression in melanoma. Nevertheless, no study has shown a correlation between PLXNC1 and miR-181a or CASC2, and their biological significance in melanoma cells.
In this study, we focused on the impact of lncRNA CASC2 on melanoma cell functions and found that CASC2 sponged miR-181a and thereby facilitated the expression of PLXNC1. The influences of CASC2 and PLXNC1 on the biological functions of melanoma cells were also investigated.
Materials and Methods

Bioinformatics analyses
The GSE86373 dataset was downloaded from the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/). The associated platform was GPL17586 Affymetrix Human Transcriptome Array 2.0. GSE86373 includes three cell lines: A375 and M6 melanoma cells and HeMa normal melanocytes. R software was applied to explore the different lncRNA and mRNA expressions between the melanoma cells and normal cells. In brief, the probe ID was converted to a gene symbol using GPL17586. Then the missing value was filled in using the impute package (k-Nearest Neighbor method). The differentially expressed lncRNAs and mRNAs were analyzed using the limma package (Bayes test and Benjamini-Hochberg correction). An adjusted P-value < 0.5 and | log 2 (fold change (FC)) | > 2 were set as thresholds for the R software to screen out the differentially expressed lncRNAs and mRNAs.
The common differentially expressed lncRNAs and mRNAs in the A375 and M6 melanoma cell lines were the potential research subjects. MiRcode (http://www.mircode.org) was used for the prediction of lncRNA targets of miRNA and TargetScan (http://www. targetscan.org) was used for the prediction of miRNA targets of mRNA. 
Tissue samples
Cell culture
Human embryonic kidney cell line 293 T, melanoma cell lines A375, C8161, HMCB, G361, WM115, MM96L, and M14, and normal human skin cell line HaCaT were all purchased from BeNa Culture Collection (BNCC, Beijing, China) and cultured in 5% CO 2 incubator at 37°C using the corresponding medium suggested by the supplier. In brief, 293 T, A375, HMCB, G361, and MM96L cells were cultured in 90% high-glucose Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, USA) with 10% fetal bovine serum (FBS; Invitrogen). C8161, WM115, and M14 cells were cultured in 90% RPMI-1640 (GIBCO BRL, Grand Island, USA) with 10% FBS (Invitrogen). HaCaT cells were cultured in 90% Minimum Essential Medium (MEM/EBSS) with 10% FBS.
Cell transfection
CASC2, miR-NC, miR-181a mimics, miR-181a inhibitor, PLXNC1, and pcDNA3.1 plasmid vector were all obtained from GenePharma Co., Ltd (Shanghai, China). Melanoma cells were seeded into 6-well plates at a concentration of 1 × 10 6 cells per well and cultured at 37°C with 5% CO 2 . When cells reached 70%-80% confluency, they were transfected with different plasmids using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, USA) according to the manufacturer's protocols.
Quantitative real-time polymerase chain reaction
Total RNA was isolated using TRIzol ® reagent (Invitrogen) and quantified with NanoDrop 2000 (Thermo Fisher Scientific). Then 200 μg of total RNA was reverse-transcribed utilizing a ReverTra Ace qPCR RT Kit (Toyobo, Tokyo, Japan). The quantitative real-time polymerase chain reaction (qRT-PCR) was performed using a THUNDERBIRD SYBR ® qPCR Mix (Toyobo). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and U6 were used as internal controls. The relative expression of mRNA was calculated by the 2 −ΔΔCT method. The primers were synthesized by Shanghai Sangon Biotech (Shanghai, China) and listed in Table 1 .
CCK-8 assay
Cell Counting Kit 8 (Biotechwell, Shanghai, China) was utilized to detect the proliferation ability of melanoma cells. A375 and M14 cells in logarithmic phase were obtained and digested with 0.25% trypsin. Single-cell suspensions were made using RPMI-1640 medium supplemented with 10% FBS. Cells (1 × 10 4 cells/ml) were seeded into 96-well plates by dispensing 100 μl of cell suspension into each well. They were then cultured in FBS-free RPMI-1640 medium in a 5% CO 2 incubator at 37°C under saturated humidity. 
Dual luciferase reporter assay
The mutant segments of CASC2 (CASC2-mut) and PLXNC1 (PLXNC1-mut) were constructed. The wild-type and mutated types of CASC2 and PLXNC1 were inserted into luciferase reporter assay vector pmirGLO (Promega, Madison, USA). Lipofectamine 2000 was employed to transfect the vectors into 293 T cells according to the manufacturer's protocols. Stably transfected cells were seeded into a 24-well plate with 5 × 10 5 cells in each well, and then transfected with 50 nM miR-181a mimics or miR-NC (GenePharma, Shanghai, China). The relative luciferase reporter activity was detected using a Luciferase Assay System (Promega) at 48 h posttransfection with a SpectraMax i3 Multimode Plate Reader (Molecular Devices, Sunnyvale, USA).
Transwell invasion assay
For cell invasion ability study, the upper Transwell chambers were coated with 200 μl Matrigel gel (BD Biosciences, San Jose, USA) at 37°C for 2 h. Next, we added a mixture of 100 μl cells (0.5-2.5 × 10 6 cells/ml) and 400 μl serum-free medium into the Transwell chambers (40 μl per well). Then, the cells were re-suspended in serum-free medium (0.5-2.5 × 10 6 cells/ml) and placed into the upper chamber (200 μl for each chamber), while the lower chamber was filled with medium containing 20% FBS. After being incubated at 37°C for 24-48 h, cells invading to the lower chambers were fixed with 4% paraformaldehyde (PA) for 20 min, stained with 0.1% crystal violet for another 20 min, and observed under a microscope with five randomly selected views. The number of cells was counted. 
Flow cytometric analysis of apoptosis
Western blot analysis
The total protein was extracted using RIPA protein lysis solution (Beyotime, Shanghai, China). A BCA Protein Assay Kit (Pierce, Rockford, USA) was employed to measure the protein concentration. Proteins (100 μg) were resolved by 15% (w/v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membrane (Thermo Fisher Scientific). The membrane was blocked with 5% skim milk in Tris-buffered saline and Tween (TBST; 15 mM Tris-HCl, pH 7.4, 0.9% NaCl, and 0.05% Tween-20) at room temperature for 1 h, followed by incubation with either anti-PLXNC1 (ab116070, 1:100) or anti-GAPDH (ab181603, 1:10,000) primary antibody (Abcam, Cambridge, USA) at 4°C overnight. After being washed three times with TBST, the membrane was treated with secondary antibody (anti-rabbit IgG, ab7090, 1:2000; Abcam) at room temperature for 1.5 h. Protein signals were detected using an enhanced chemiluminescence (ECL) Plus (Thermo Fisher Scientific) and the gray value of each protein band was determined using Lab Works 4.5 image analysis software. GAPDH protein was detected as the internal control.
Statistical analyses
All experiments were repeated at least three times and all data are presented as the mean ± standard deviation. Data of all groups were checked up with normal test. Normally distributed data were analyzed by paired-sample t test or independent-sample t test. Data not conformed to a normal distribution were tested by Kruskal-Wallis test. Statistical analysis was done by SPSS 17.0. In all instances twotailed test was used. Level of statistical significance was set at P < 0.05.
Results
Microarray analysis results
The GSE86373 gene chip from platform GPL17586 [HTA-2_0] Affymetrix Human Transcriptome Array 2.0 [transcript (gene) version] was analyzed to screen out differentially expressed lncRNAs in melanoma cell lines and normal melanocytes based on the criteria of a difference > 2-fold and P < 0.05 (Fig. 1) . The common differentially expressed lncRNA in the A375 (Fig. 1A,B) and M6 CASC2  5′-TTCACCGACATAGTCTCTTG-3′  5′-CCATCACTTGACCTCCTTC-3′  miR-181a  5′-TTGAGGTTGCTTCAGTGA-3′  5′-GGAGTAGATGATGGTTAGC-3′  PLXNC1  5′-TGATGTTCTCCTTCGGTTCTTG-3′  5′-TTCCTCCTCCTGATGTCTTCTC-3′  GAPDH  5′-AACGGATTTGGTCGTATTG-3′  5′-GGAAGATGGTGATGGGATT-3′  U6 5′-CTCGCTTCGGCAGCACA-3′ 5′-AACGCTTCACGAATTTGCGT-3′
( Fig. 1C,D ) melanoma cell lines compared with HeMa normal melanocytes was identified as CASC2. Thus, CASC2 was selected as the research object.
CASC2 is down-regulated in melanoma tissues and cells
Total RNA was extracted from each of the 11 pairs of melanoma tissues and adjacent normal tissues. The expression level of CASC2 was determined by qRT-PCR. It was found that CASC2 had dramatically lower expression in melanoma tissues than in adjacent normal tissues ( Fig. 2A ; P < 0.05). Total RNA was extracted from each of the seven melanoma cell lines (A375, C8161, HMCB, G361, WM115, MM96L, and M14) and from the normal human skin cell line HaCaT to measure the expression of CASC2 by qRT-PCR. The expression of CASC2 was significantly lower in melanoma cell lines than in normal skin cell line ( Fig. 2B ; P < 0.05).
CASC2 inhibits proliferation and invasiveness of melanoma cells
To further investigate the influence of CASC2 expression on melanoma cell functions, such as cell proliferation and invasion, overexpression experiment was done in two melanoma cell lines, A375 and M14. CASC2 was transfected into the cells to up-regulate the lncRNA CASC2 expression level, while cells in the control groups were transfected with a negative control vector (vector-NC). qRT-PCR assay verified that CASC2 expression in the CASC2-transfected cells was remarkably up-regulated ( Fig. 3A ; P < 0.05).
CCK-8 assay was carried out to determine the proliferation of melanoma cells. The results showed that the proliferation of tumor cells transfected with CASC2 was dramatically reduced compared with the NC-transfected cells ( Fig. 3B ; P < 0.05). The flow cytometry results indicated that cell apoptosis rate was notably increased in the CASC2-transfected cells compared with the NC-transfected cells ( Fig. 3C ; P < 0.05). Results of the Transwell assay showed that tumor cell invasiveness was distinctly declined in the cells transfected with CASC2 compared with that in the negative control cells ( Fig. 3D ; P < 0.05).
CASC2 directly interacts with miR-181a
As the preceding experiments demonstrated the influence of CASC2 on melanoma cells, we therefore further explored whether CASC2 could directly interact with miR-181a in which complementary sequences with CASC2 were discovered by miRcode (Fig. 4A) . Plasmid pmirGLO with wild-type CASC2 (CASC2-wt) containing the predicted complementary sequences or with CASC2 mutant (CASC2-mut) was transfected into A375 melanoma cells. According to the dual luciferase reporter assay results, in the CASC2-wt group, fluorescence intensity of cells with miR-181a mimics was distinctly lower than those with miR-NC; while in the CASC2-mut group, fluorescence intensity displayed no significant variation after being transfected with miR-181a mimics or miR-NC ( Fig. 4B ; P < 0.05).
The expression level of miR-181a in patients' tissue samples was measured by qRT-PCR. The results showed that miR-181a expression was increased in patients' tumor tissues ( Fig. 4C ; P < 0.05). After transfection of the A375 and M14 melanoma cell lines A375 with CASC2 or vector-NC, miR-181a expression was significantly decreased in the CASC2-transfected cells ( Fig. 4D ; P < 0.05).
MiR-181a promotes proliferation and invasiveness of melanoma cells
In order to explore whether miR-181a can affect melanoma cell functions via CASC2, A375 and M14 cells were transfected with vector-NC, miR-NC, miR-181a mimics, miR-181a inhibitor, or miR-181a mimics+CASC2. qRT-PCR validated that miR-181a expression was dramatically increased in the miR-181a mimics group and declined in the miR-181a inhibitor group, while miR181a expression in miR-181a mimics+CASC2 group showed no significant difference compared with the vector-NC control group ( Fig. 5A ; P < 0.05). CCK-8 assay, flow cytometry, and Transwell assay were carried out to determine cell viability, apoptosis rate, and invasion, respectively. Compared with the control group, cell viability and invasion ability in the miR-181a mimics group were remarkably enhanced, while cell apoptosis rate was declined. In the miR-181a inhibitor group, cell viability and invasion ability were significantly abated, while apoptosis rate went up. Compared with the miR-181 mimics group, cell viability and invasion ability in the miR-181a mimics+CASC2 group were obviously down-regulated and apoptosis rate was increased, while compared with the control group, cell viability and invasion ability in miR-181a mimics +CASC2 group showed no significant difference ( Fig. 5B-D ; P < 0.05).
Apoptosis-associated protein PLXNC1 is suppressed by miR-181a
The downstream proteins regulated by miR-181a were predicted by bioinformatics analysis. Microarray analysis (data not shown) and TargetScan prediction revealed two potential mRNAs: SLC16 A6 and PLXNC1 (down-regulated in the melanoma cells A357 and M6 and targeted by miR-181a). From the National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov/gene/), PLXNC1 was shown to be a possible tumor suppressor gene for melanoma (Gene ID: 10154), while SLC16A6 had no association with melanoma (Gene ID: 9120). Therefore, PLXNC1 was selected for further investigation. To explore whether PLXNC1 is regulated by miR-181a and CASC2, we first determined the interaction between PLXNC1 and miR-181a. Dual luciferase reporter assay verified that CASC2 could directly interact with miR-181a ( Fig. 6A,  B ; P < 0.05). Then, we determined the mRNA and protein expression of PLXNC1 by qRT-PCR and western blot analysis. It was found that PLXNC1 expression in the miR-181a mimics group was distinctly down-regulated, but was up-regulated in the CASC2 group and miR-181a inhibitor group. The expression of PLXNC1 in the miR-181a mimics+CASC2 group was remarkably upregulated compared with the miR-181a mimics group, but showed no significant difference compared with the control group ( Fig. 7A,  B ; P < 0.05).
To explore the impact of PLXNC1 expression level on melanoma cell proliferation, apoptosis, and invasiveness, A375 and M14 melanoma cells were transfected with PLXNC1 cDNA to up-regulate PLXNC1 expression, while the control cells were transfected with vector-NC. Cell proliferation was determined by the CCK-8 assay. Cell proliferation in the PLXNC1-transfected cells was significantly reduced (Fig. 7C, P < 0.05) . Flow cytometry was performed to detect cell apoptosis. The cell apoptosis rate Figure 5 . CASC2 neutralized miR-181a overexpression in melanoma cells (A) qRT-PCR verified high expression of miR-181a in the miR-181a mimics group and low expression of miR-181a in miR-181a inhibitor group. (B) CCK-8 assay results showed that compared with the control group, cell viability in miR-181a mimics group was dramatically increased; compared with miR-181a mimics group, cell viability in miR-181a mimics+CASC2 group was notably reduced, while compared with miR-NC group, there was no significant difference. (C) Flow cytometry results showed that cell apoptosis rate in miR-181a mimics group was dramatically decreased compared with that in the control group; cell apoptosis rate in miR-181a mimics+CASC2 group was notably boosted when compared with that in the miR-181a mimics group, while compared with the miR-NC group, no significant difference was found. (D) Transwell assay showed that cell invasiveness was significantly improved in miR-181a mimics group when compared with the control group; compared with miR-181a mimics group, cell invasiveness in miR-181a mimics+CASC2 group was remarkably reduced, while no significant difference was found when compared with miR-NC group. * P < 0.05 indicated significant difference compared with control group at 24 h. Scale bar: 20 μm.
in the PLXNC1-transfected groups was notably increased ( Fig. 7D ; P < 0.05). Finally, Transwell assay was conducted to measure cell invasiveness. The invasiveness of cells overexpressing PLXNC1 was dramatically declined compared with that of the control cells ( Fig. 7E ; P < 0.05).
Discussion
The present study demonstrated that lncRNA CASC2 was expressed at a significantly low level in melanoma tissues and that its overexpression could inhibit the viability and invasive capacity of melanoma tumor cells. Following bioinformatics analysis, dual luciferase reporting assay and expression correlation experiments confirmed that CASC2 may act as a competing endogenous RNA (ceRNA) to sponge miR-181a and facilitate the expression of PLXNC1 in melanoma cells. The present results implicate miR-181a and PLXNC1 as an oncogene and a tumor-suppressing gene, respectively. These results demonstrate that lncRNA CASC2 plays a critical role in the biological functions of melanoma cells by regulating miR-181a and PLXNC1. Accumulating evidence has confirmed that various lncRNAs are aberrantly expressed in melanoma cells and serve as either a cancer promoter or a suppressor. For instance, overexpression of lncRNA MALAT1 was found in melanoma tissues and cells, which promoted cell growth by regulating miR-183 [25] , and lncRNA PVT1 was reported as a new diagnostic biomarker, whose overexpression could enhance tumor progression [26] , while lncRNA NKILA was found to be down-regulated in malignant melanoma, acting as an inhibitor via the regulation of NF-κB [27] . In this study, we screened out the differently expressed lncRNA CASC2, and attempted to find its association with melanoma. Researchers have explored the dysregulation of CASC2 in many cancers. For example, Xiong et al. [13] revealed that low expression of CASC2 indicates a poor prognosis and can promote cell proliferation of thyroid carcinoma. Pei et al. [26] illustrated that low expression of CASC2 inhibits the activation of Wnt/β-catenin signal pathway and promotes cell proliferation and metastasis of bladder cancer. Palmieri et al. [5] reported that CASC2 is a tumor suppressor in endometrial cancer, colorectal cancer, nonsmall cell lung cancer, renal cell carcinoma, gliomas, and gastric cancer. Our results first revealed down-regulation of CASC2 in melanoma cells. We also demonstrated that overexpression of lncRNA CASC2 could suppress melanoma cell proliferation and invasion, while boosting cell apoptosis. All of these results indicate the inhibitory effects of CASC2 on melanoma cells.
A growing body of evidence suggests that many lncRNAs may function as ceRNAs to prevent a single miRNA or multiple miRNAs from binding to their regulatory targets [7] . Previous studies have found this new biological mechanism of lncRNA CASC2 in several cancers. For instance, Feng et al. [28] found that CASC2 up-regulates PTEN expression by directly inhibiting miR-21 in cisplatin-resistant cervical cancer cells. Huang et al. [7] revealed that CASC2 can suppress colorectal tumor growth by sponging miR-18a. Here, we found that miR-181a is a target miRNA of CASC2 by bioinformatics analysis. The interaction between CASC2 and miR-181a has been explored in glioma cells [29] , while our study is the first to investigate their functions in melanoma cells. The results of our experiments illustrate that miR-181a is negatively regulated by CASC2. A significantly high expression level of miR181a was found in melanoma tissues. Meanwhile, overexpression of miR-181a dramatically promoted tumor cell viability, which could be notably neutralized by CASC2.
To further investigate the mechanism of CASC2/miR-181a interaction in melanoma cells, we selected a downstream protein PLXNC1 which is targeted by miR-181a. It has been reported that PLXNC1 is expressed at high levels in normal human melanocytes both in vitro and in vivo [30] . A few studies focused on the influence of PLXNC1 on melanomas, finding that PLXNC1 could inhibit melanoma proliferation and metastasis [30, 31] . In our study, upregulation of PLXNC1 was found to delay melanoma cell progression, which is consistent with previous studies. In addition, we also found that PLXNC1 was negatively correlated with miR-181a, but could be positively regulated by CASC2. Therefore, we confirmed that lncRNA CASC2 can competitively bind to miR-181a, and thereby promote the expression of PLXNC1, leading to the inhibition of melanoma development.
Nevertheless, this study still has few limitations. For instance, we only explored the mechanism and impacts in vitro, therefore, these results should be further confirmed by in vivo experiments. We only focused on the CASC2/miR-181a/PLXNC1 axis in melanoma cells, while CASC2 may have other functions such as regulation of the Wnt/β-catenin pathway [26, 32] . Thus, further investigations are required to validate these results and achieve a comprehensive understanding of the regulation mechanism in melanoma cancer.
In conclusion, we demonstrated low expression of CASC2 and high expression of miR-181a in melanoma tissues and cells. The anti-tumor function of CASC2 and PLXNC1 was recognized, while miR-181a was found to have tumor-promoting activity. CASC2 may serve as a ceRNA to sponge miR-181a and facilitate the expression of PLXNC1. These findings collectively provide a new direction in the targeted treatment of melanoma cancer. . Apoptosis-associated protein PLXNC1 was suppressed by miR-181a (A,B) Compared with the control group, PLXNC1 expression in miR-181a mimics group was significantly reduced, while PLXNC1 expression was remarkably increased in miR-181a inhibitor group and CASC2 group; compared with the miR-181a mimics group, PLXNC1 expression in miR-181a mimics+CASC2 group was dramatically increased, while no significant difference was found when compared with the control group. (C) CCK-8 assay revealed decreased cell viability after tumor cells A375 and M14 were transfected with PLXNC1. (D) Flow cytometry showed increased cell apoptosis rate after tumor cells A375 and M14 were transfected with PLXNC1. (E) Transwell assay demonstrated decreased cell invasiveness after tumor cells A375 and M14 were transfected with PLXNC1. * P < 0.05 indicated significant difference compared with NC group. Scale bar: 20 μm.
